<SEC-DOCUMENT>0001558370-17-004768.txt : 20170612
<SEC-HEADER>0001558370-17-004768.hdr.sgml : 20170612
<ACCEPTANCE-DATETIME>20170612163035
ACCESSION NUMBER:		0001558370-17-004768
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170609
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170612
DATE AS OF CHANGE:		20170612

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		17906653

	BUSINESS ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>f8-k.htm
<DESCRIPTION>8-K
<TEXT>
<!--HTML document created with Merrill Bridge  7.1.52.0-->
<!--Created on: 6/12/2017 2:30:06 PM-->
<html>
	<head>
		<title>
			glyc_Current Folio 8k
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt;border-top:3pt double #000000 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 14pt;">
			<font style="display:inline;">UNITED STATES</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 14pt;">
			<font style="display:inline;font-weight:bold;font-size:14pt;">SECURITIES AND EXCHANGE COMMISSION</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-weight:bold;">Washington, DC 20549</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1.2pt;color:black;background-color:black;" align="center"></hr></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 14pt;">
			<font style="display:inline;font-weight:bold;font-size:14pt;">FORM 8&#8209;K</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">CURRENT REPORT</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">Pursuant to Section 13 or 15(d) of</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">The Securities Exchange Act of 1934</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">Date of Report (Date of earliest event reported): June 9, 2017</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div><hr style="border-width:0;width:25%;height:1.2pt;color:black;background-color:black;" align="center"></hr></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 14pt;">
			<font style="display:inline;font-weight:bold;font-size:14pt;">GlycoMimetics, Inc.</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">(Exact name of registrant as specified in its charter)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td valign="top" style="width:29.44%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:03.74%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:31.78%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.54%;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:29.44%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;text-decoration:underline;">Delaware</font></p>
				</td>
				<td valign="bottom" style="width:03.74%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:31.78%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;text-decoration:underline;">001-36177</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.54%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-weight:bold;font-size:9pt;text-decoration:underline;">06-1686563</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:29.44%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">(State or other jurisdiction of&nbsp;incorporation)</font></p>
				</td>
				<td valign="bottom" style="width:03.74%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:31.78%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">(Commission File Number)</font></p>
				</td>
				<td valign="bottom" style="width:02.50%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:32.56%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
						<font style="display:inline;font-size:9pt;">(IRS Employer<br />Identification No.)</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">9708 Medical Center Drive</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">Rockville, MD 20850</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">(Address of principal executive offices, including zip code)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">(240) 243-1201</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">(Registrant&#x2019;s telephone number, including area code)</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-weight:bold;font-size:9pt;">N/A</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">(Former name or former address, if changed since last report)</font>
		</p>
		<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:5pt 0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font>
		</p>
		<p style="margin:5pt 0pt 5pt 14.25pt;text-indent: -14.25pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">[&nbsp;&nbsp;] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font>
		</p>
		<p style="margin:5pt 0pt 5pt 14.25pt;text-indent: -14.25pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">[&nbsp;&nbsp;] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font>
		</p>
		<p style="margin:5pt 0pt 5pt 14.25pt;text-indent: -14.25pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">[&nbsp;&nbsp;] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font>
		</p>
		<p style="margin:0pt 0pt 0pt 14.25pt;text-indent: -14.25pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">[&nbsp;&nbsp;] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font>
		</p>
		<p style="margin:0pt 0pt 0pt 14.25pt;text-indent: -14.25pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Ind&#xED;cate by check mark whether the registrant is an emerging growth Company as defined in Rule 405 of the Securities Act of 1933 (&#xA7;230.405 of this chapter) or Rule 12b&#8209;2 of the Securities Exchange Act of 1934 (&#xA7;240.12b&#8209;2 of this chapter).</font>
		</p>
		<p style="margin:0pt 0pt 0pt 14.25pt;text-indent: -14.25pt;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">Emerging growth company &#x2611;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 9pt;">
			<font style="display:inline;font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#x2611;</font>
		</p>
		<p style="margin:0pt;border-bottom:3pt double #000000 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			&nbsp;
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:5pt 0pt 12pt 45pt;text-indent: -45pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Item 5.02&nbsp;&nbsp;Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;">On June 9, 2017, the Board of Directors (the &#x201C;</font><font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Board</font><font style="display:inline;font-size:10pt;">&#x201D;) of GlycoMimetics, Inc. (the &#x201C;</font><font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Registrant</font><font style="display:inline;font-size:10pt;">&#x201D;) appointed Patricia S. Andrews&nbsp;to serve as a director of the Company and a member of the Audit Committee of the Board.&nbsp;&nbsp;Ms. Andrews will serve as a Class III director whose term will expire at the 2020 annual meeting of stockholders.&nbsp; There is no arrangement or understanding between Ms. Andrews and any other person pursuant to which she was selected as a director of the Company, and there is no family relationship between Ms. Andrews and any of the Company&#x2019;s other directors or executive officers.&nbsp;&nbsp;The Company is not aware of any transaction involving Ms. Andrews requiring disclosure under Item 404(a) of Regulation S-K. Additional information about Ms. Andrews is set forth below.</font>
		</p>
		<p style="margin:12pt 0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;"></font><font style="display:inline;font-weight:bold;font-style:italic;font-size:10pt;">Patricia S. Andrews</font><font style="display:inline;font-size:10pt;">, age 59, has served as a member of our Board since June 2017.&nbsp;&nbsp;Ms. Andrews has served as Chief Executive Officer of Boston Biomedical, Inc., an oncology drug research and development company, since April 2017 and previously served as its Chief Operating Officer from November 2013 to April 2017.&nbsp;&nbsp;From October 2008 to August 2012, Ms. Andrews served as Chief Commercial Officer of Incyte Corporation, a publicly held biopharmaceutical company.&nbsp;&nbsp;From 1991 to 2008, Ms. Andrews served in various roles of increasing responsibility at Pfizer Inc., culminating in her role as Vice President and General Manager of Pfizer&#x2019;s U.S. Oncology business unit.&nbsp;&nbsp;Ms. Andrews received her B.A. degree from Brown University and her M.B.A. degree in Finance from the University of Michigan.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;;font-size: 10pt;font-family:Times New Roman,Times,serif;text-indent:0pt;margin-left:0pt;padding:0pt 36pt 0pt 0pt;"></font><font style="display:inline;font-size:10pt;">In accordance with the Company&#x2019;s compensation policy for non-employee directors, upon her appointment as a director, Ms. Andrews was granted a nonqualified stock option to purchase 22,000 shares of the Company&#x2019;s common stock at an exercise price of $11.63, the closing price of the Company&#x2019;s common stock on the date of grant.&nbsp;&nbsp;This option will vest and become exercisable in three equal installments on the first, second and third anniversaries of the date of grant, subject to Ms. Andrews&#x2019;s Continuous Service (as defined in the Company&#x2019;s 2013 Equity Incentive Plan) as of each vesting date.&nbsp;&nbsp;Additionally, Ms. Andrews will be entitled to receive a $35,000 annual retainer for her service as director and a $7,500 annual retainer for her service on the Audit Committee.&nbsp;&nbsp;At each annual stockholder meeting following which Ms. Andrews&#x2019;s term as a director continues, Ms. Andrews will be entitled to receive an additional nonqualified stock option to purchase 11,000 shares of the Company&#x2019;s common stock, which option will vest and become exercisable over a one-year period following the date of grant.&nbsp;&nbsp;Ms. Andrews has also entered into the Company&#x2019;s standard form of indemnification agreement.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">Item 7.01&nbsp; Regulation FD Disclosure.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">On June 12, 2017, the Company issued a press release announcing Ms. Andrews&#x2019;s appointment to the Board.&nbsp; A copy of this press release is furnished herewith as Exhibit&nbsp;99.1 to this Current Report.</font><font style="display:inline;color:#000000;font-size:10pt;"> The information contained in the press release furnished as Exhibit 99.1 shall not be deemed &#x201C;filed&#x201D; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#x201C;</font><font style="display:inline;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;">Exchange Act</font><font style="display:inline;color:#000000;font-size:10pt;">&#x201D;), and is not incorporated by reference into any of the Company&#x2019;s filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;color:#000000;font-size:10pt;">Item 9.01 Exhibits.</font><font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">(d)&nbsp;Exhibits</font>
		</p>
		<p style="margin:0pt;border-top:1pt none #D9D9D9 ;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:40.00pt;padding:0pt 0.7pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:06.20pt;height:1.00pt;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:343.15pt;padding:0pt 0.7pt 0pt 0pt;height:1.00pt">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:40.00pt;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Exhibit</font></p>
				</td>
				<td valign="top" style="width:06.20pt;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:343.15pt;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:40.00pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Number</font></p>
				</td>
				<td valign="top" style="width:06.20pt;padding:0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:343.15pt;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Exhibit&nbsp;Description</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:40.00pt;border-top:1pt solid #000000 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt 0pt 0pt 7.2pt;text-indent: -7.2pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">99.1</font></p>
				</td>
				<td valign="top" style="width:06.20pt;padding:0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:343.15pt;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Press Release dated June 12, 2017, &#x201C;GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors.&#x201D; &nbsp; &nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt;line-height:100%;text-align:center;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">SIGNATURES</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;text-indent:37.05pt;text-align:justify;text-justify:inter-ideograph;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;margin-left:0pt;">
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:58.92%;padding:0pt;">
					<p style="margin:0pt;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:41.08%;padding:0pt;">
					<p style="margin:0pt;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">GLYCOMIMETICS, INC.</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:58.92%;padding:0pt;">
					<p style="margin:0pt;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:41.08%;padding:0pt;">
					<p style="margin:0pt;font-weight:bold;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:55.56%;padding:0pt;">
					<p style="margin:0pt;text-align:right;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-right:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;width:03.36%;padding:0pt;">
					<p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">By:</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:41.08%;border-bottom:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">/s/ Brian M. Hahn</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;width:58.92%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Date:&nbsp; June 12, 2017</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;width:41.08%;border-top:1pt solid #000000 ;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Brian M. Hahn</font></p>
				</td>
			</tr>
			<tr>
				<td colspan="2" valign="top" style="border-right:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:58.92%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="border-left:1pt none #D9D9D9 ;border-top:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;width:41.08%;padding:0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Chief Financial Officer</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;"></font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;"></font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;"></font>
		</p>
		<p style="margin:0pt 0pt 12pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-weight:bold;font-size:10pt;">EXHIBIT INDEX</font>
		</p>
		<div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;margin-left:0pt;">
			<tr>
				<td valign="bottom" style="width:10.10%;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Exhibit</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:88.52%;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;</font></p>
				</td>
			</tr>
			<tr>
				<td valign="bottom" style="width:10.10%;border-bottom:1pt solid #000000 ;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Number</font></p>
				</td>
				<td valign="bottom" style="width:01.38%;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
				</td>
				<td valign="bottom" style="width:88.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;line-height:normal;text-align:center;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-weight:bold;font-size:10pt;">Exhibit&nbsp;Description</font></p>
				</td>
			</tr>
			<tr>
				<td valign="top" style="width:10.10%;border-top:1pt solid #000000 ;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:11.25pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>99.1
				</td>
				<td valign="bottom" style="width:01.38%;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">&nbsp;</font></p>
				</td>
				<td valign="top" style="width:88.52%;padding:0pt 0.7pt 0pt 0pt;">
					<p style="margin:5pt 0pt 6pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
						<font style="display:inline;font-size:10pt;">Press Release dated June 12, 2017, &#x201C;GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors.&#x201D; &nbsp; &nbsp;</font></p>
				</td>
			</tr>
		</table></div>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p>
		<p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;">
			<font style="display:inline;font-size:10pt;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p><div style="width:100%">

		<p style="margin:24pt 0pt 0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 12pt;">

			&nbsp;

		</p>

</div></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex-99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--HTML document created with Merrill Bridge  7.1.52.0-->
<!--Created on: 6/12/2017 2:30:04 PM-->
<html>
	<head>
		<title>
			glyc_Ex99_1
		</title>
	</head>
	<body><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p style="margin:0pt 0pt 12pt;text-align:right;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;">Exhibit 99.1</font>
		</p>
		<p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;"><img src="ex-99d1g001.jpg" style="width: 3.76in; height: 0.82in" alt="Picture 1"></font>
		</p>
		<p style="margin:0pt;line-height:100%;border-bottom:1pt none #D9D9D9 ;text-align:center;font-family:Courier New;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 41.75pt;line-height:100%;text-indent:30.25pt;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;text-align:center;font-family:Courier New;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">GLYCOMIMETICS APPOINTS BOSTON BIOMEDICAL </font><font style="display:inline;font-family:Calibri;text-transform:none;">CEO</font><font style="display:inline;font-family:Calibri;">&nbsp;</font>
		</p>
		<p style="margin:0pt 41.75pt;line-height:100%;text-indent:30.25pt;border-top:1pt none #D9D9D9 ;text-align:center;font-family:Courier New;font-weight:bold;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;">PATRICIA S. ANDREWS TO ITS BOARD OF DIRECTORS</font>
		</p>
		<p style="margin:0pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="text-transform:uppercase;display:inline;font-family:Calibri;font-weight:bold;">ROCKVILLE, MD, June 12, 2017 </font><font style="text-transform:uppercase;display:inline;font-family:Calibri;">&#x2013; &nbsp;</font><font style="display:inline;font-family:Calibri;font-size:11pt;">GlycoMimetics, Inc.&nbsp;(NASDAQ: GLYC) announced today the appointment of&nbsp;Patricia S. Andrews, chief executive officer and director of Boston Biomedical, Inc., to its Board of Directors.&nbsp; </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">&#x201C;It&#x2019;s an asset to our Board and GlycoMimetics as a whole to be able to leverage Pat&#x2019;s commercial experience in oncology," said&nbsp;</font><font style="display:inline;"><a href="#">Rachel King</a></font><font style="display:inline;font-family:Calibri;color:#0563C1;font-size:11pt;"></font><font style="display:inline;font-family:Calibri;font-size:11pt;">, CEO of&nbsp;GlycoMimetics. "Her track record of leadership in transitioning companies to the commercial stage will be particularly helpful to us as we continue to advance our pipeline.&#x201D; </font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Ms. Andrews was named CEO of&nbsp;Boston Biomedical in April 2017. She joined the company in 2013 and was most recently its Executive Vice President and Chief Operating Officer, where she prepared for launching the company&#x2019;s first product, and guided the company&#x2019;s pipeline development. Previously, she was Executive Vice President and Chief Commercial Officer at Incyte Corporation (NASDAQ: INCY), leading commercial operations for that company&#x2019;s launch of first-in-class, first-in-disease oncology product Jakafi&#xAE;. Before that, she served in leadership positions at Pfizer, Inc., where her final role was Vice President and General Manager of the U.S. Oncology Business Unit, and at Marine Midland/HSBC, where she was Vice President in corporate finance. Ms. Andrews received her M.B.A. from the University of Michigan and her B.A. from Brown University.</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 11pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">"I'm honored to serve on the Board of Directors of&nbsp;GlycoMimetics, which has impressed me with its management team and promising pipeline of treatments targeting some of today&#x2019;s most serious medical challenges in oncology," said&nbsp;Ms. Andrews. "I believe these clinical assets have potential in areas of high unmet need, and I look forward to helping the company rapidly progress its drug candidates towards commercialization."</font>
		</p>
		<p style="margin:0pt 0pt 8pt;line-height:106.67%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-size:11pt;">Ms. Andrews was introduced to GlycoMimetics through an initiative sponsored by </font><font style="display:inline;"><a href="#">LifeSci Advisors</a></font><font style="display:inline;font-family:Calibri;font-size:11pt;"> for the placement of women on boards of directors in the life sciences industry. &#x201C;On behalf of the GlycoMimetics management and Board, I&#x2019;d like to thank LifeSci Advisors for its </font><font style="display:inline;"><a href="#">Board Placement Initiative</a></font><font style="display:inline;font-family:Calibri;font-size:11pt;">, which assisted in helping to identify several outstanding director candidates, including Pat,&#x201D; Ms. King added.</font>
		</p>
		<p style="margin:5pt 0pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;color:#000000;">About&nbsp;GlycoMimetics, Inc.</font>
		</p>
		<p style="margin:5pt 0pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;color:#000000;">GlycoMimetics is a clinical-stage biotechnology company focused on cancer and sickle cell disease. GlycoMimetics&#x2019; most advanced drug candidate, rivipansel, a pan-selectin antagonist, is being developed for the treatment of vaso-occlusive crisis in sickle cell disease and is being evaluated in a Phase 3 clinical trial being conducted by its strategic collaborator, Pfizer. GlycoMimetics' wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated in an ongoing Phase </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr><p style="page-break-after:always">&nbsp;</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><p style="margin:5pt 0pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;"><font style="display:inline;font-family:Calibri;color:#000000;">1/2 clinical trial as a potential treatment for AML and in a Phase 1 clinical trial in multiple myeloma. The U.S. FDA recently granted GMI-1271 Breakthrough Therapy designation for treatment of adult AML patients with relapsed/refractory disease. GlycoMimetics has also recently initiated a clinical trial with a third drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more</font><font style="display:inline;font-family:MS Mincho;color:#000000;">&#x2028;</font><font style="display:inline;font-family:Calibri;color:#000000;">at www.glycomimetics.com. </font>
		</p>
		<p style="margin:5pt 0pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;color:#000000;">Forward-Looking Statements</font>
		</p>
		<p style="margin:5pt 0pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;color:#000000;">This press release contains forward-looking statements regarding GlycoMimetics' planned activities with respect to the clinical development and potential commercialization of its product pipeline. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the outcomes of planned and ongoing clinical trials, expectations for regulatory approvals and other factors discussed in the "Risk Factors" section of GlycoMimetics' Annual Report on Form 10-K that was filed with the&nbsp;U.S. Securities and Exchange Commission&nbsp;on&nbsp;March 1, 2017, and other filings&nbsp;GlycoMimetics&nbsp;makes with the&nbsp;Securities and Exchange Commission&nbsp;from time to time. In addition, the forward-looking statements included in this press release represent GlycoMimetics' views as of the date hereof.&nbsp;GlycoMimetics&nbsp;anticipates that subsequent events and developments may cause its views to change. However, while&nbsp;GlycoMimetics&nbsp;may elect to update these forward-looking statements at some point in the future,&nbsp;GlycoMimetics&nbsp;specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing GlycoMimetics' views as of any date subsequent to the date hereof.<img src="ex-99d1g002.gif" style="width: 0.00625in; height: 0.00625in" alt="CT?id=bwnews&amp;sty=20170420005978r1&amp;sid=acqr7&amp;distro=nx&amp;lang=en"></font>
		</p>
		<p style="margin:5pt 0pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;color:#000000;">Source: GlycoMimetics, Inc.<br /></font>
		</p>
		<p style="margin:5pt 0pt;background-color: #FFFFFF;color:#000000;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;font-family:Calibri;font-weight:bold;color:#000000;">Investor Contact:<br /></font><font style="display:inline;font-family:Calibri;color:#000000;">Shari Annes, 650-888-0902<br /></font><font style="display:inline;font-family:Calibri;">sannes@annesassociates.com<br /></font><font style="display:inline;font-family:Calibri;color:#000000;">or<br /></font><font style="display:inline;font-family:Calibri;font-weight:bold;color:#000000;">Media Contact:<br /></font><font style="display:inline;font-family:Calibri;color:#000000;">Jamie Lacey-Moreira, 410-299-3310<br /></font><font style="display:inline;font-family:Calibri;">jamielacey@presscommpr.com</font>
		</p>
		<p style="margin:0pt 0pt 12pt;line-height:100%;font-family:Times New Roman,Times,serif;font-size: 12pt;">
			<font style="display:inline;">&nbsp;</font>
		</p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;">
		<p><font size="1"> </font></p></div><div style="margin-left:10.2941176470588%;margin-right:10.2941176470588%;"><hr align="center" style='background-color:#000000; border-width:0; color:#000000; height:2pt; lineheight:0; width:100%;'></hr></div>
	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex-99d1g001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d1g001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !     %$2
M  0    !             8:@  "QC__; $, " 8&!P8%" <'!PD)" H,% T,
M"PL,&1(3#Q0=&A\>'1H<'" D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T
M,O_; $,!"0D)# L,& T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,O_  !$( $X!:0,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M)Y_B'P'?6UF.7N+6<3;!ZD 8'XD5V^@>(M+\3Z8NH:3=+/ 3ANS(W]UAU!H
MU:*YGP-XK?QAHD^H26BVICNI+?8K[L[<<YP/6NFH **** "BBB@ HHHH **Q
MH/$$4VJFQ\DK\[()"W!(SV]\5J7,ZVMK+._W8U+$>M7*$HM)K<B-2,DVGL2T
M5F:3K*:J90L)C,>.K9SG/^%5UUYCKIT_[/\ )O*;L\Y]?I3]E.[5MB?;0LG?
M<VZ***S-0HHHH **** "BLJ;6O*UI-.^SYW$#S-_J,],?UJ&ZUYK?6EL1;[E
M+*I;//..GYUHJ4WTZ7,G6@NO6QMT445F:A1110 4444 %%<]XF\5)X;OM#MG
MM&G.JWR6:L'V^66(&X\<]>E=#0 4444 %%%% !1110!Y%XI_Y.+\*_\ 7B/Y
MSU):?ZW4?^PG>_\ I3)4?BG_ ).+\*_]>(_G/4EI_K=1_P"PG>_^E,E=>#_B
M/T_R./'?PUZ_YEFBBBO2/*"BBB@ KEO&'^J^%7_77_V>"NIKEO&'^J^%7_77
M_P!G@KAQNT3T<!]KY'HOQ5UNXT+X>ZC<6C%+B;;;HX."F\X)'OMSCWQ6GX+\
M+6GA'PW;:=;Q(LVP-<R <RRX^8D_7IZ"H/B'X<E\4^"-0TVWQ]J*B6 'NZG(
M'XX(_&J?P^\;VOB;28K.ZD\C7;1?*N[27Y9-R\%@#R0>_H>#7 >@=A)/!$=L
MLL:$CHS 9JAI&F:+I?GII%M:6_GN991;@#<Q[G'U^@K*\5^$/"6MD:IXEM8V
M%M%M\^6Y>)43)/.U@.I/6N&^$VC:?+XQU_Q%H=D]IH(3[%9!F8^;RI=OF)/5
M >?[V.QH J>$)M:M/@[K-[H%R8;^TU*:<#RU?S$4*67# ]LGCG(%>L^'];M_
M$/AVQUBWP(KJ$2$9^X>C*3[$$?A7$_!4!O!5Z" 0=3G!!^BUQVI:E?\ @?\
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MEM>?&LGLS_\ H-'B_P#UUK_NM_2G%1YXPY5JA2<^253F>C([F\U];<:@S>5
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M9(E\L,3][! !;OPH'H37H7A#X8Z!X1"3Q0_;-1')O+@ L#_LCHOX<^]=I10
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
E110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>ex-99d1g002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex-99d1g002.gif
M1TE&.#EA 0 ! ($  ,# P            "'_"TY%5%-#05!%,BXP P$!   A
9^00!     "P      0 !   (!  !! 0 .P$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
